Xing xing Xie

Mr. Xing xing Xie


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2024 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
SGShan Gao
Shan Gao
LFLing Fan
Ling Fan
ZYZhigang Yu
Zhigang Yu
XXXing xing Xie
Xing xing Xie
Lurasidone is an atypical anti‑psychotic approved by the US Food and Drug Administration. It is mainly used to treat schizophrenia in adults through its antagonistic action on dopamine and 5‑hydroxytryptamine receptors. The present study systematically assessed the efficacy and safety of lurasidone in the treatment of schizophrenia. Clinical, double‑blind, parallel, randomized controlled trials (RCTs) of lurasidone in the treatment of schizophrenia were retrieved from PubMed\Medline, EBSCO, Embase, Cochrane Library, OVID, Web of Science and related clinical trial registration websites up to May 2023. A total of two investigators independently screened the included references and evaluated their quality. RevMan 5.3 software was used for meta‑analysis of each measure outcome. The present systematic review was registered in PROSPERO (ID=CRD42018108178). A total of eight RCTs were included in the present study, including a total of 2,456 patients with schizophrenia. All eight references were randomized, double‑blind and parallel control trials. All eight references were evaluated as high quality. The meta‑analysis results demonstrated that there were no significant change in total Positive and Negative Syndrome Scale (PANSS) score, Clinical Global Impression of Severity (CGI‑S) score and Montgomery‑Asberg Depression Rating Scale (MADRS) between the 40 mg lurasidone group and the placebo group (P>0.05). However, as the dosage increased, the 80, 120 and 160 mg lurasidone groups had significant changes in total PANSS score, CGI‑S score and MADRS Compared with placebo (P0.05). In terms of safety, the changes in the incidence of agitation in the 40 mg lurasidone group (P<0.05), vomiting in the 80 mg group (P<0.05) and akathisia in the 160 mg group (P<0.05) were statistically significant and there were also statistically significant changes in the incidence of akathisia, nausea, somnolence and extrapyramidal disorder among the 40, 80 and 120 mg lurasidone groups (P0.05). In conclusion, existing evidence suggests that the initial dose of lurasidone for schizophrenia can be adjusted to 80 mg. As the condition aggravates, the dose can be incrementally increased to 160 mg. A dose of 160 mg lurasidone is recommended as the most efficacious and safe dose for acute schizophrenia and the risk of occurrence of akathisia, nausea, somnolence and extrapyramidal disorder is still high when lurasidone is administered at a dose of 80‑120 mg. The dose should be promptly adjusted or the drug should be withdrawn if the aforementioned adverse reactions worsen. Multi‑center, high‑quality and long‑term clinical RCTs influenced by the included references are still necessary to support the aforementioned conclusions.

8 November 2024 in Medicine
Verified
Journal Article
Open access
XXXing xing Xie
Xing xing Xie
XFXiaodong Mm Fan
Xiaodong Mm Fan
FLFan Ling
Fan Ling
XLXue Mm Liu
Xue Mm Liu
YZYang Zheng
Yang Zheng
ZYZhigang Yu
Zhigang Yu
Background: The combination of methimazole and propranolol is considered an effective treatment regimen for hyperthyroidism in clinical practice; however, detrimental effects on the heart rate, bone metabolism and thyroid hormone levels have been reported. Therefore, the present study aimed to systematically review the efficacy and safety differences in patients with hyperthyroidism and the effects of treatment on heart rate, bone metabolism, cortisol, and adrenocorticotropic hormone levels using case–control studies. Methods: Clinical case–control trials of methimazole combined with propranolol for the treatment of hyperthyroidism were selected from Chinese and English databases, and data were collected from the establishment of the database until August 2024. Two independent researchers evaluated the quality of the literature using the Newcastle–Ottawa Scale (NOS). Meta-analysis of each effect index was performed using RevMan software (version 5.3), and the quality of the results was evaluated using the GRADE profiler system letter description method. Results: Sixteen clinical case–control trials were included in this study. Of these, 2 trials exhibited NOS scores of 7, 6 trials exhibited NOS scores of 6, and 8 trials exhibited NOS scores of 5. These accounted for 12.5% of the high-quality literatures, and included 772 patients treated with methimazole combined with propranolol (observation group) and 771 patients treated with methimazole alone (control group). The results of the meta-analysis demonstrated that methimazole combined with propranolol improved the cure rate, the total effective rate, and heart rate, compared with the control group (P < .05). In addition, calcification, bone glutamate protein, free triiodothyronine, free tetraiodothyronine, thyroid-stimulating hormone, cortisol, and adrenocorticotropic hormone were significantly different between the 2 groups (P < .05). There were no significant differences in leukemia, headache, dizziness, skin pruritus, bone pain, arthralgia, or in improving parathyroid hormone or reducing gastrointestinal reactions between the 2 groups. Conclusion: The present study demonstrated that methimazole combined with propranolol may significantly improve the heart rate, bone metabolism and associated hormone levels in patients with hyperthyroidism, without significantly increasing the risk of adverse reactions. However, due to the impact of primary literature type, quality or research methods high-quality, multicenter, rigorously designed clinical trials are required for further verification.

19 April 2024 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
XXXing xing Xie
Xing xing Xie
XLXue Liu
Xue Liu
RLRong Li
Rong Li
LFLing Fan
Ling Fan
FHFujing Huang
Fujing Huang
Atherosclerotic cardiovascular disease (ASCVD) is one of the most common chronic diseases in the world. Epidemiological evidence and clinical trials have shown that ω‑3 fatty acids have a variety of promoting effects in reducing the risk of ASCVD, but different conclusions of large randomized controlled trials make their clinical use in the prevention and treatment of ASCVD controversial. The present review focuses on the pharmacological mechanism, clinical trials and evidence value of clinical applications of ω‑3 fatty acids in order to provide theoretical and practical evidence for the clinical application strategy, and follow‑up research and development of ω‑3 fatty acids as anti‑ASCVD drugs.

28 March 2026 in European Journal of Pharmacology
Verified
Journal Article
Closed access
CWCheng Wang
Cheng Wang
KXKe Xu
Ke Xu
LZLing-Li Zheng
Ling-Li Zheng
YZYang Zheng
Yang Zheng
XXXing xing Xie
Xing xing Xie

26 June 2026 in Medicine
Verified
Journal Article
Open access
JZJie Zhang
Jie Zhang
XFXiaodong Fan
Xiaodong Fan
XXXing xing Xie
Xing xing Xie
Background: Intra-abdominal infections are a common complication of colorectal cancer surgery. Postoperative abdominal infections can cause systemic inflammatory response syndrome, which seriously affects the prognosis of patients. With the widespread application of antibiotics, the detection rate of drug-resistant bacteria has increased annually, resulting in increased pressure on antibiotic treatment selection. To improve the prognosis of postoperative patients with colorectal cancer, it is important to actively search for risk factors leading to postoperative abdominal infection and formulate effective intervention measures according to these risk factors. Methods: A comprehensive search was conducted using several databases, including China National Knowledge Infrastructure, Wanfang Data, VIP, CBM, PubMed, Embase, and OVID, until September 2025. Case-control studies focusing on postoperative abdominal infections in colorectal cancer were conducted, and a meta-analysis was performed using the RevMan 5.4 software. Results: A total of 21 case-control studies were included, and 42 risk factors for infection were identified. The results indicated that significant differences ( P < .05) existed between the postoperative abdominal infection and non-infection groups concerning various factors, including diabetes mellitus, hypertension, cardiovascular disease, hypoproteinemia, tumor-node-metastasis stage I, tumor location, and several perioperative variables: operation time exceeding 150 minutes, hospital stay of 30 days or more, drainage tube indentation lasting over 10 days, serum albumin levels, preoperative hemoglobin levels, incision length > 15 cm, blood loss exceeding 300 mL, laparoscopic surgery, postoperative fistula, preoperative intestinal obstruction, anemia, anastomotic fistula, combined organ resection, preoperative ASA score, perioperative blood transfusion, and reoperation. Conclusion: Given the multitude of identified risk factors for postoperative abdominal infections in colorectal cancer, medical institutions should prioritize the prevention and control of hospital infections. This includes developing targeted strategies based on identified risk factors, careful assessment of surgical indications for colorectal cancer patients during clinical diagnosis and treatment, strict adherence to surgical protocols, and enhancing organ function support for patients post-surgery to reduce the incidence of postoperative abdominal infections.

29 March 2024 in Biomedical Reports
Verified
Journal Article
Open access
PDF file
XXXing xing Xie
Xing xing Xie
JZJie Zhang
Jie Zhang
FHFujing Huang
Fujing Huang
FLFan Ling
Fan Ling
Abrocitinib is a highly selective Janus kinase 1 (JAK1) inhibitor that can block a multitude of inflammatory signaling pathways that underlie atopic dermatitis (AD). In addition, abrocitinib inhibits JAK1 signaling in sensory neurons to alleviate acute and chronic pruritus during AD. However, substantial variations in efficacy and safety risks remain due to variations in doses applied in clinical use. Therefore for the present study, differences in the efficacy and tolerability of 100 and 200 mg abrocitinib for treating pruritus and eczema symptoms in patients with moderate‑to‑severe AD were evaluated compared with placebo. Specifically, randomized controlled trials (RCTs) of abrocitinib compared with placebo for the treatment of moderate‑to‑severe AD were searched on Pubmed, E.B. Stephens Company, China National Knowledge Infrastructure, Wanfang Medical network, Web of Science and related Clinical Trials Registry up to November 2023. In total, two researchers evaluated the quality of the included literature according to the Cochrane Handbook of Systematic Reviews. RevMan 5.3 software was used to conduct a meta‑analysis of the efficacy and safety indicators in a cross‑comparison of the effects exerted by placebo and 100 and 200 mg abrocitinib. A total of 1,825 patients with moderate‑to‑severe AD were included across five double‑blind, placebo RCTs. Compared with the placebo group, during the double‑blind trial period, significant improvements were observed in the investigator's global assessment score, response rate of eczema area and severity index (EASI)‑50, EASI‑75, EASI‑90 and pruritus numerical rating scale (P‑NRS) in the 100 and 200 mg abrocitinib groups (P<0.05). However, pairwise control analysis of the 100 and 200 mg group yielded significant differences (P<0.05) in all of the aforementioned therapeutic indicators except for the P‑NRS score. In terms of safety, compared with the placebo group, there were significantly higher incidence of nausea, upper respiratory tract viral infection, infections and infestations in the 100 mg abrocitinib group (P<0.05). In addition, there were significantly higher incidence of nausea, gastrointestinal disorder, headache and dizziness in the 200 mg group (P<0.05). There were also significant differences in the incidence of nausea, gastrointestinal disorder and dizziness between the 100 and 200 mg groups (P<0.05). For patients with moderate‑to‑severe AD, oral administration of 100 or 200 mg abrocitinib once/day was concluded to ameliorate skin pruritus and eczema symptoms to varying degrees, with the efficacy significantly superior at the 200 mg dose. However, the risk of a number of adverse reactions, such as headache, dizziness, nausea and gastrointestinal dysfunction, is also significantly increased. Therefore, patients should be made aware of the risk of adverse drug effects prior to the administration of long‑term high abrocitinib doses. Furthermore, large‑scale, multi‑center, rigorous clinical trials remain necessary to validate the findings from the present study.